Semaglutide
A GLP-1 receptor agonist that slows gastric emptying and affects gut-brain appetite signaling.
View medication pageTherapy Hub
Gut Health
Gut health therapies often center on signaling pathways that shape appetite, gastric motility, nutrient handling, and the broader gut-brain connection. In this category, semaglutide and tirzepatide fit because they act on incretin pathways that influence gastric emptying, satiety, and metabolic signaling, even though their most established clinical role remains weight management rather than a direct gastrointestinal disease indication.
Available Medications
Each medication below is grouped here because its mechanism, clinical use, or published literature helps explain why it fits this therapy category.
Tirzepatide
A dual GIP/GLP-1 agonist that acts on incretin pathways tied to appetite regulation and the gut-brain axis.
View medication pageMore Medications Available
This is not a comprehensive list of our available medications. We have what you need.
Contact us for moreReferences
Studies, data, and supporting evidence
These references support the positioning statements used on this therapy hub. They are intended as educational source material for patients and prescribers, not as a substitute for individualized medical judgment.
WEGOVY (semaglutide) Prescribing Information
Official labeling notes that semaglutide slows stomach emptying, which is one of the clearest reasons it belongs in a gut-brain and motility-focused category.
Full Text →Once-Weekly Semaglutide in Adults with Overweight or Obesity
Landmark STEP 1 trial showing clinically meaningful weight loss with semaglutide, reinforcing how modulation of GLP-1 pathways changes appetite and downstream metabolic outcomes.
PubMed →GLP-1 Receptor Agonists and Delayed Gastric Emptying
Review summarizing the relationship between GLP-1 signaling and delayed gastric emptying, with direct relevance to semaglutide's gut effects.
Full Text →ZEPBOUND (tirzepatide) Prescribing Information
Official labeling describes tirzepatide as both a GIP and GLP-1 receptor agonist, directly supporting its placement in an incretin and gut-brain signaling category.
Full Text →Tirzepatide: A Novel, Once-Weekly Dual GIP and GLP-1 Receptor Agonist
Clinical review explaining tirzepatide's dual incretin pharmacology and why its gut-hormone effects differ from a pure GLP-1 agent.
Full Text →Evidence strength is not identical across all therapies. Some placements are supported by FDA labeling or landmark randomized trials, while others rely more heavily on mechanistic, adjunctive, or early-stage literature and should be framed accordingly.